Details

Autor(en) / Beteiligte

• Nitayaphan, Sorachai
• Khamboonruang, Chirasak
• Sirisophana, Narongrid
• Morgan, Patricia
• Chiu, Joseph
• Duliege, Anne-Marie
• Chuenchitra, Cheodchai
• Supapongse, Thippawan
• Rungruengthanakit, Kittipong
• deSouza, Mark
• Mascola, John R
• Boggio, Kit
• Ratto-Kim, Silvia
• Markowitz, Lauri E
• Birx, Deborah
• Suriyanon, Vinai
• McNeil, John G
• Brown, Arthur E
• Michael, Rodney A

Titel

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

Ist Teil von

• Vaccine, 2000-02, Vol.18 (15), p.1448-1455

Ort / Verlag

Oxford: Elsevier Ltd

Erscheinungsjahr

2000

Quelle

Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Beschreibungen/Notizen

• Fifty-two human immunodeficiency virus type 1, seronegative Thai adults from the community were enrolled in a double-blind, placebo controlled, phase I/II trial of HIV SF2 gp120/MF59 vaccine to determine the safety and immunogenicity of this recombinant, B clade, HIV envelope protein vaccine. Twenty-six subjects were enrolled at each of two sites in Thailand, Bangkok and Chiang Mai. Twelve subjects received placebo and 40 subjects received vaccine (50 μg). Subjects were immunized according to one of two schedules, 0, 1 and 4 or 0, 1 and 6 months. The frequency of adverse reactions was not different between placebo and vaccine subjects, nor between immunization schedules. Of vaccinees, all developed high-titer binding antibody to the immunogen (rgp120), 39 developed neutralizing antibody (NA) responses against homologous virus (HIV-1 SF2), and 22 developed NA against heterologous virus (HIV-1 MN). No subject demonstrated intercurrent HIV infection, however screening EIA reactivity occurred in 27% of recipients. Thus, this candidate HIV vaccine was found to be safe and immunogenic in Thai adults, laying the foundation for development of a subtype E construct in this population.